ZW 25

Drug Profile

ZW 25

Alternative Names: ZW-25

Latest Information Update: 28 Apr 2017

Price : $50

At a glance

  • Originator Zymeworks
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ovarian cancer
  • Preclinical Breast cancer; Gastric cancer

Most Recent Events

  • 01 Apr 2017 Efficacy and adverse events data from a preclincial trial presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 17 Feb 2017 ZW 25 receives Orphan Drug status for Gastric cancer in USA
  • 01 Sep 2016 Phase-I clinical trials in Ovarian cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top